Skip to main content
KPRX
NASDAQ Life Sciences

Kiora Q3 10-Q: Going-Concern Warning, $6.2M Nine-Month Loss, KIO-104 Shelved

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.4
Mkt Cap
$5.973M
52W Low
$1.33
52W High
$2.91
52W Position info
5.3% above low
Off High info
52% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

KPRX is trading near its 52-week low of $1.33 (5.3% above the low).

Summary

Kiora's Q3 2026 10-Q shows a $1.75M quarterly net loss, cash down to $5.57M, and an explicit going-concern warning, offset by $1.0M of CKD collaboration revenue and the October pivot to KIO-401 with KIO-104 discontinued.


Key Events · Earnings and Guidance · KPRX

  • Going-Concern Warning Disclosed

    Management states substantial doubt about the Company's ability to continue as a going concern, with cash and short-term investments of $5.6 million and $10.7 million at September 30, 2026 funding operations only into late 2027, excluding the technology transfer milestone.

  • Q3 Loss Widens, Cash Burns Down

    Net loss was $1.75 million for Q3 2026 versus $26,806 of net income a year earlier; nine-month net loss reached $6.25 million versus $4.32 million. Cash and equivalents fell to $5.57 million from $8.70 million at December 31, 2025.

  • KIO-104 Discontinued, Impairment Ahead

    In October 2026 Kiora discontinued KIO-104 development, not for safety or efficacy reasons. It will test the $1.0 million in-process R&D asset for impairment in Q4 2026 and may reverse up to $1.7 million of contingent consideration liabilities.

  • CKD Deal Books $1.0M Revenue

    The August 2026 Chong Kun Dang license for KIO-301 in Korea generated $1.0 million of collaboration revenue in Q3 2026, net of $165,000 Korean withholding tax, with up to $15.5 million in milestones plus 10% royalties still eligible.


Analysis · KPRX · Life Sciences

Kiora's balance sheet is thinner than it looks. Cash and equivalents dropped to $5.57M from $8.70M at year-end, and total liquidity of roughly $16.3M ($5.57M cash plus $10.72M short-term investments) is now committed against a $3.5M Senju upfront payment plus a $12.5M technology transfer milestone that may come due before the stated late-2027 runway. Management explicitly states substantial doubt about the ability to continue as a going concern, so another raise is close to certain — and the April 2026 private placement already added 438,471 shares plus warrants for up to 11.36M more shares. The offsetting positive is that the pivot to KIO-401 is real: the CKD deal booked $1.0M of collaboration revenue in Q3, and discontinuing KIO-104 frees cash and could reverse up to $1.7M of contingent consideration. The near-term mechanical risk is the Tranche A-1 warrants: 7,864,726 shares at $1.94 expire November 28, 2026 unless exercised, and with the stock at $1.40 they are far out of the money — a large chunk of potential financing that will likely vanish.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KPRX was trading at $1.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $1.33 to $2.91. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KPRX - Latest Insights

KPRX
Oct 29, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.58
Real-time Price: $1.33 info
Change: -$1.25 (-48%) info
Market Cap: $5.884M info
KPRX
Aug 19, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.65
Real-time Price: $1.33 info
Change: -$1.32 (-50%) info
Market Cap: $5.884M info
KPRX
Aug 07, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.58
Real-time Price: $1.33 info
Change: -$1.25 (-48%) info
Market Cap: $5.884M info
KPRX
Jun 18, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.57
Real-time Price: $1.33 info
Change: -$1.24 (-48%) info
Market Cap: $5.884M info
KPRX
Jun 18, 2026, 7:00 AM EDT
Source: TMX Newsfile
Importance Score:
7
Price at Filing: $2.57
Real-time Price: $1.33 info
Change: -$1.24 (-48%) info
Market Cap: $5.884M info